BST1 and acute myeloid leukemia: CD157 is widely expressed in M4 and M5 subtypes of acute myeloid leukaemia (AML)3, notably in the patient group characterised by adverse prognosis according to the European LeukemiaNet (ELN) classification and CD157 is currently under investigation as a target for antibody-based immunotherapy in AML16,17.